Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

European Urology
Urs E StuderEORTC Genitourinary Group

Abstract

EORTC trial 30891 compared immediate versus deferred androgen-deprivation therapy (ADT) in T0-4 N0-2 M0 prostate cancer (PCa). Many patients randomly assigned to deferred ADT did not require ADT because they died before becoming symptomatic. The question arises whether serum prostate-specific antigen (PSA) levels may be used to decide when to initiate ADT in PCa not suitable for local curative treatment. PSA data at baseline, PSA doubling time (PSADT) in patients receiving no ADT, and time to PSA relapse (>2 ng/ml) in patients whose PSA declined to <2 ng/ml within the first year after immediate ADT were analyzed in 939 eligible patients randomly assigned to immediate (n=468) or deferred ADT (n=471). In both arms, patients with a baseline PSA>50 ng/ml were at a>3.5-fold higher risk to die of PCa than patients with a baseline PSA<or=8 ng/ml. If baseline PSA was between 8 and 50 ng/ml, the risk of PCa death was approximately 7.5-fold higher in patients with PSADT<12 mo than in patients with PSADT>12 mo. Time to PSA relapse after response to immediate ADT correlated significantly with baseline PSA, suggesting that baseline PSA may also reflect disease aggressiveness. Patients with a baseline PSA>50 ng/ml and/or a PSADT<12 mo were a...Continue Reading

References

Apr 1, 1980·The Journal of Allergy and Clinical Immunology·S R Hirsch, J H Kalbfleisch
Jun 8, 2001·International Journal of Radiation Oncology, Biology, Physics·R ChooG Hruby
Feb 12, 2002·The Journal of Clinical Endocrinology and Metabolism·Matthew R SmithPhilip W Kantoff
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Urs E StuderDaniel Dietrich
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eeva K SalminenMartti Nurmi
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Milena Braga-BasariaShehzad Basaria

❮ Previous
Next ❯

Citations

Oct 12, 2012·Der Urologe. Ausg. A·M Spahn, K Haeni
May 23, 2013·Der Urologe. Ausg. A·G HatibogluS Pahernik
Dec 10, 2009·Wiener medizinische Wochenschrift·Ingrid BergerStephan Madersbacher
Jan 11, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN European Society for Medical Oncology
Nov 24, 2011·Prostate Cancer·Kristene Myklak, Shandra Wilson
Sep 1, 2009·Therapeutic Advances in Medical Oncology·Matthew A UhlmanLeon Sun
Jan 1, 2009·Cancer Management and Research·Shandra Wilson
Dec 11, 2013·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
Dec 7, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonUNKNOWN Oncology Committee of the French Association of Urology (CCAFU)
Feb 10, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L Boccon-GibodM Zerbib
May 30, 2014·Endocrine-related Cancer·Carolyn A AllanKati L Matthiesson
Feb 4, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonUNKNOWN Les membres du CCAFU
May 1, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·B FallB A Diagne
Aug 30, 2011·European Urology·Vincenzo PagliaruloUrs E Studer
Nov 9, 2010·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
Dec 26, 2015·Der Urologe. Ausg. A·J Hess
Oct 20, 2009·Critical Reviews in Oncology/hematology·Jean-Pierre DrozCora N Sternberg
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Theo M de Reijke, Thomas Wiegel
Feb 5, 2008·European Urology·John Anderson
Apr 7, 2009·BJU International·Paul Hoffmann, Claude Schulman
Mar 3, 2009·BJU International·Kurt MillerPer-Anders Abrahamsson
Apr 17, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Magdalena LyckenAnna Bill-Axelson
Feb 14, 2015·Current Geriatrics Reports·Maxim J McKibben, Angela B Smith
Jun 29, 2016·Prostate Cancer and Prostatic Diseases·J L KiwataC M Dieli-Conwright
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence Collette, Urs E Studer
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A GardinerDavid L Nicol
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kurt Miller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Yu-Ning WongKatrina Armstrong
The New England Journal of Medicine
Michel BollaEORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group
© 2021 Meta ULC. All rights reserved